Context Therapeutics Inc.
CNTX evidence brief
What we can confirm
- BioSniper Score:
- 6.5 / 10
- Market Cap:
- $32.2M
- Lead Asset:
- CT-202 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for CNTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CNTX
Context Therapeutics Inc. (CNTX) is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors, with a pipeline including CTIM-76, CT-202, and CT-95.
Key risk: Pre-revenue stage
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$32.2M
Cash Runway
—
Lead Asset
CT-202 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 4 clinical trials for Context Therapeutics Inc..
Context Therapeutics Inc. (CNTX) is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors, with a pipeline including CTIM-76, CT-202, and CT-95.
- Cash and cash equivalents of $43.0 million as of June 30, 2026, expected to fund operations into Q4 2027 [news · 2026-08-05].
- Net income of -$14.6 million and shareholders' equity of $38.2 million as of June 30, 2026 [sec].
- Lead program CTIM-76 (CLDN6 x CD3) received FDA Fast Track designation for platinum-resistant ovarian cancer in April 2026 [news · 2026-04-02].
- Initial clinical readouts for CTIM-76 and CT-202 programs expected beginning in Q2 2027 [news · 2026-08-05].
- CT-202 (Nectin-4 x CD3) Phase 1 trial first patient dosed in September 2026 [news · 2026-09-09].
What works
- Cash runway into Q4 2027 provides a multi-year operational buffer without near-term financing pressure [news · 2026-08-05].
- FDA Fast Track designation for CTIM-76 may accelerate development and review for platinum-resistant ovarian cancer [news · 2026-04-02].
- Pipeline includes three Phase 1 programs (CTIM-76, CT-95, CT-202) targeting distinct solid tumor antigens with TCE bispecific technology [pipeline].
What to weigh
- Company is pre-revenue with a net loss of $14.6 million in the latest reported period, typical for a clinical-stage biotech [sec].
- All pipeline candidates are in Phase 1, with no approved products or later-stage data to de-risk clinical or regulatory outcomes [pipeline].
- CTIM-76 faces competition from BioNTech (BNT211), TORL (TORL-1-23), and Daiichi Sankyo (DS9606a) in the CLDN6 space [pipeline].
- CT-202 competes with Pfizer's Padcev and Bicycle Therapeutics' BT8009 in the Nectin-4 space [pipeline].
From the filings
Quoted directly from source documents.
Cash position and runway
“Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027”
News · August 5, 2026
FDA Fast Track for CTIM-76
“FDA has granted Fast Track designation to CTIM-76, the Company's investigational Claudin 6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer”
News · April 2, 2026
Expected initial clinical readouts
“initial clinical readouts expected beginning in Q2 2027”
News · August 5, 2026
Catalyst timeline
- 2026-09-01 · Phase 1 start for CT-202 — First patient dosed in Phase 1a/1b trial of CT-202 for triple-negative breast, urothelial, and colorectal cancers.
- 2025-03-31 · Phase 1 start for CT-95 — Phase 1a/1b study of CT-95 in advanced cancers associated with mesothelin expression initiated.
- 2024-07-10 · Phase 1 start for CTIM-76 — First-in-human Phase 1 study of CTIM-76 for recurring ovarian cancer and other advanced solid tumors began.
- 2022-12-02 · Phase 2 start for ELONA (elacestrant + onapristone) — Phase 1b-2 study of elacestrant in combination with onapristone for ER+/PR+/HER2- breast cancer initiated.
Risks & what to watch (4)›
Key risks
- Pre-revenue stage — No approved products or revenue; net loss of $14.6M as of 2026-06-30 [sec].
- Early-stage pipeline — All three programs are Phase 1; no Phase 2/3 data to confirm efficacy [pipeline].
- Competitive landscape — CTIM-76 and CT-202 face multiple competitors with similar targets [pipeline].
- Dependence on partnerships — Programs rely on partners (Integral Molecular, BioAtla) for technology and milestones [pipeline].
What to watch
- Initial clinical readouts for CTIM-76 and CT-202 expected beginning Q2 2027 [news · 2026-08-05].
- Phase 1 dose-escalation data for CT-95 as it approaches target dose levels [news · 2025-11-05].
- Cash burn rate and any changes to cash runway beyond Q4 2027 [news · 2026-08-05].
- Regulatory updates or additional Fast Track designations for pipeline candidates [news · 2026-04-02].
Sources: Catalysts · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run Context Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Context Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.21 · 0% dilution
Lead: Phase 1
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
59
Total value held
$205.8M
| Holder | Shares | Value |
|---|---|---|
| mpm bioimpact llc | 10,679,391 | $28.0M |
| avidity partners management lp | 9,996,534 | $24.9M |
| deep track capital, lp | 7,419,355 | $19.4M |
| nextech invest, ltd. | 7,419,355 | $19.4M |
| soleus capital management, l.p. | 6,963,141 | $18.2M |
| octagon capital advisors lp | 5,250,000 | $13.8M |
| blue owl capital holdings lp | 5,089,015 | $13.3M |
| franklin resources inc | 3,803,338 | $10.0M |
| vanguard capital management llc | 3,431,953 | $9.0M |
| marshall wace, llp | 2,948,441 | $7.7M |
Showing top 10 of 59 institutional holders of Context Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.1%
- Days to cover
- 1.0
- Shares short
- 898,683
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CNTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Context Therapeutics Inc.?
Context Therapeutics Inc. (CNTX) is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors, with a pipeline including CTIM-76, CT-202, and CT-95.
What is Context Therapeutics Inc.'s lead drug candidate?
Context Therapeutics Inc.'s most advanced tracked candidate is CT-202 (Phase 1) for Triple Negative Breast Cancer (TNBC).
Who is the CEO of Context Therapeutics Inc.?
Mr. Martin A. Lehr is the chief executive officer of Context Therapeutics Inc. (CNTX).
Where is Context Therapeutics Inc. headquartered?
Context Therapeutics Inc. (CNTX) is headquartered in Philadelphia, PA, United States.
What therapeutic areas does Context Therapeutics Inc. focus on?
Context Therapeutics Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.